| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
biomarker quantification
with high-fat high-sucrose diet |
Bile acids in feces. | DO population | both | 4-26wks | 2018 |
|
|
biomarker quantification | TMAO, choline, phosphocholine, glycerophosphocholine, betaine, carnitine. | both | 8-20wks | 2021 | |
|
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
biomarker quantification
with iron-containing diet |
Plasma hepcidin levels. | inbred (9) | m | 10wks | 2017 |
|
|
biomarker quantification | Temporal cortex amyloid level, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
biomarker quantification
with high-fat diet |
Bile acid levels in plasma, feces, and liver. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
biomarker quantification | Fibronectin. | inbred (25) | both | 9wks | 2007 |
|
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |